Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial

Cavendish reiterated a ‘buy’ rating on Poolbeg Pharma as its first patient dosing begins a value-creating period, setting a 19p target versus 7.4p (about 170% upside). The stock was up ~5% on the day, suggesting the note provides a near-term positive catalyst based on early clinical progress.

Analysis

Cavendish reiterated a ‘buy’ rating on Poolbeg Pharma as its first patient dosing begins a value-creating period, setting a 19p target versus 7.4p (about 170% upside). The stock was up ~5% on the day, suggesting the note provides a near-term positive catalyst based on early clinical progress.